Journal:AI meets exascale computing: Advancing cancer research with large-scale high-performance computing
| Full article title | AI meets exascale computing: Advancing cancer research with large-scale high-performance computing |
|---|---|
| Journal | Frontiers in Oncology |
| Author(s) |
Bhattacharya, Tanmoy; Brettin, Thomas; Doroshow, James H.; Evrard, Yvonne A.; Greenspan, Emily J.; Gryshuk, Amy L.; Hoang, Thuc T.; Vea Lauzon, Carolyn, B.; Nissley, Dwight; Penberthy, Lynne; Stahlberg, Eric; Stevens, Rick; Streitz, Fred; Tourassi, Georgia; Xia, Fangfang; Zaki, George |
| Author affiliation(s) |
Los Alamos National Laboratory, Argonne National Laboratory, National Cancer Institute, Frederick National Laboratory for Cancer Research, Lawrence Livermore National Laboratory, National Nuclear Security Administration, U.S. Department of Energy Office of Science, University of Chicago, Oak Ridge National Laboratory |
| Primary contact | Email: george dot zaki at nih dot gov |
| Editors | Meerzaman, Daoud |
| Year published | 2019 |
| Volume and issue | 9 |
| Page(s) | 984 |
| DOI | 10.3389/fonc.2019.00984 |
| ISSN | 2234-943X |
| Distribution license | Creative Commons Attribution 4.0 International |
| Website | https://www.frontiersin.org/articles/10.3389/fonc.2019.00984/full |
| Download | https://www.frontiersin.org/articles/10.3389/fonc.2019.00984/pdf (PDF) |
 |
This article should be considered a work in progress and incomplete. Consider this article incomplete until this notice is removed. |
Abstract
The application of data science in cancer research has been boosted by major advances in three primary areas: (1) data: diversity, amount, and availability of biomedical data; (2) advances in artificial intelligence (AI) and machine learning (ML) algorithms that enable learning from complex, large-scale data; and (3) advances in computer architectures allowing unprecedented acceleration of simulation and machine learning algorithms. These advances help build in silico ML models that can provide transformative insights from data, including molecular dynamics simulations, next-generation sequencing, omics, imaging, and unstructured clinical text documents. Unique challenges persist, however, in building ML models related to cancer, including: (1) access, sharing, labeling, and integration of multimodal and multi-institutional data across different cancer types; (2) developing AI models for cancer research capable of scaling on next-generation high-performance computers; and (3) assessing robustness and reliability in the AI models. In this paper, we review the National Cancer Institute (NCI) -Department of Energy (DOE) collaboration, the Joint Design of Advanced Computing Solutions for Cancer (JDACS4C), a multi-institution collaborative effort focused on advancing computing and data technologies to accelerate cancer research on the molecular, cellular, and population levels. This collaboration integrates various types of generated data, pre-exascale compute resources, and advances in ML models to increase understanding of basic cancer biology, identify promising new treatment options, predict outcomes, and, eventually, prescribe specialized treatments for patients with cancer.
Keywords: cancer research, high-performance computing, artificial intelligence, deep learning, natural language processing, multi-scale modeling, precision medicine, uncertainty quantification
Introduction
Predictive computational models for patients with cancer can in the future support prevention and treatment decisions by informing choices to achieve the best possible clinical outcome. Toward this vision, in 2015, the national Precision Medicine Initiative (PMI)[1] was announced, motivating efforts to target and advance precision oncology, including looking ahead to the scientific, data, and computational capabilities needed to advance this vision. At the same time, the horizon of computing was changing in the life sciences, as the capabilities and transformations enabled by exascale computing were coming into focus, driven by the accelerated growth in data volumes and anticipated new sources of information catalyzed by new technologies and initiatives such as PMI.
The National Strategic Computing Initiative (NSCI) in 2015 named the Department of Energy (DOE) as a lead agency for “advanced simulation through a capable exascale computing program” and the National Institutes of Health (NIH) as one of the deployment agencies to participate “in the co-design process to integrate the special requirements of their respective missions.” This interagency coordination structure opened the avenue for a tight collaboration between the NCI and the DOE. With shared aims to advance cancer research while shaping the future for exascale computing, the NCI and DOE established the Joint Design of Advanced Computing Solutions for Cancer (JDACS4C) in June of 2016 through a five-year memorandum of understanding with three co-designed pilot efforts to address both national priorities. The high-level goals of these three pilots were to push the frontiers of computing technologies in specific areas of cancer research:
- at the cellular level: advance the capabilities of patient-derived pre-clinical models to identify new treatments;
- at the molecular level: further understand the basic biology of undruggable targets; and
- at the population level: gain critical insights on the drivers of population cancer outcomes.
The pilots would also develop new uncertainty quantification (UQ) methods to evaluate confidence in the AI model predictions.
Using co-design principles, each of the pilots in the JDACS4C collaboration is based on—and driven by—team science, which is the hallmark of the collaboration's success. Enabled by deep learning, Pilot One (cellular-level) combines data in innovative ways to develop computationally predictive models for tumor response to novel therapeutic agents. Pilot Two (molecular-level) combines experimental data, simulation, and AI to provide new windows to understand and explore the biology of cancers related to the Ras superfamily of proteins. Pilot Three (population-level) uses AI and clinical information at unprecedented scales to enable precision cancer surveillance to transform cancer care.
References
- ↑ "What is the Precision Medicine Iniative?". Genetics Home Reference. National Institutes of Health. 2019. https://ghr.nlm.nih.gov/primer/precisionmedicine/initiative. Retrieved 20 September 2019.
Notes
This presentation is faithful to the original, with only a few minor changes to presentation. In some cases important information was missing from the references, and that information was added.
